3rd Circuit Weighs In On Product-Hopping

WilmerHale
Contact

On Sept. 28, 2016, in Mylan Pharmaceuticals Inc. v. Warner Chilcott Public Limited Co. (Doryx), the Third Circuit affirmed the lower court’s grant of summary judgment rejecting antitrust claims brought against Warner Chilcott for alleged “product hopping” with respect to its drug Doryx (delayed-release doxycycline hyclate). The court distinguished other product-hopping cases —including the recent Second Circuit decision in Namenda — and held that the plaintiff, generic drug manufacturer Mylan, failed to put forth sufficient evidence that Warner Chilcott possessed monopoly power or engaged in anti-competitive conduct. While its decision turned on the particular facts of the case, the Third Circuit rejected several sweeping arguments that antitrust plaintiffs regularly advance in pharmaceutical antitrust cases.

Originally published in Law360 - October 31, 2016.

Please see full Article below for more information.

LOADING PDF: If there are any problems, click here to download the file.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© WilmerHale | Attorney Advertising

Written by:

WilmerHale
Contact
more
less

WilmerHale on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.